The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Panitumumab + mFOLOFOX6 as the new standard of care for RAS WT metastatic colorectal cancer
Takayuki Yoshino, MD, PhD , National Cancer Center Hospital, Chiba, Japan, talks on the Phase III PARADIGM trial (NCT02394795), the results of which established a new standard of care (SOC) of panitumumab plus mFOLOFOX6 for patients with RAS wild-type metastatic colorectal cancer (mCRC). The PARADIGM study compared the anti-EGFR panitumumab versus the anti-VEGFR bevacizumab with mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC), demonstrating a higher overall-survival with panitumumab . This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
